• Citer

Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group

par Wildiers, Hans;Cardoso, Fatima ;Brain, Etienne;Tryfonidis, Konstantinos;Dal Lago, Lissandra ;Vuylsteke, Peter;Curigliano, Giuseppe;Waters, Simon;Brouwers, Barbara;Altintas, Sevilay;Touati, Nathan
Référence Lancet oncology, 19, 3, page (323-336)
Publication Publié, 2018-03

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group
Auteur:	Wildiers, Hans; Cardoso, Fatima; Brain, Etienne; Tryfonidis, Konstantinos; Dal Lago, Lissandra; Vuylsteke, Peter; Curigliano, Giuseppe; Waters, Simon; Brouwers, Barbara; Altintas, Sevilay; Touati, Nathan
Informations sur la publication:	Lancet oncology, 19, 3, page (323-336)
Statut de publication:	Publié, 2018-03
Sujet CREF:	Cancérologie
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1470-2045
	info:doi/10.1016/S1470-2045(18)30083-4
	info:pii/S1470204518300834
	info:scp/85042610370